VEGF165 Overview
Molecule Name
Vascular endothelial growth factor A
Synonyms
RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
Drug Development Progress
Drugs in Clinical Trials56
Approved Drugs55
Highest Development StageApproved
Target Synonym
Vascular Endothelial Growth Factor，VEGF-A，MVCD1，Vascular endothelial growth factor A，VEGF，VEGFA，VPF，Vascular Endothelial Growth Factor A165，Vascular permeability factor，Vascular Endothelial Growth Factor A121
Background
VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
VEGF165 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ixoberogene soroparvovec | ADVM-022 | Phase 3 Clinical | Weill Cornell Medical College | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar(Jiangsu Aosaikang) | ASK-1202; AMD-B; AK-3008; ASK-B1202; ASKB1202 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Details |
| Ranibizumab biosimilar (Reliance Life Sciences Group) | R-TPR-024 | Phase 3 Clinical | Reliance Life Sciences | Macular Degeneration | Details |
| Tovecimig | ES-104; NOV-1501; CTX-009; HD-B001A; HDB001A; TR-009; ABL001; ABL-001 | Phase 3 Clinical | Abl Bio Inc | Ampullary Carcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Glioblastoma; Rectal Neoplasms; Solid tumours | Details |
| Bevacizumab biosimilar (Huaota Biopharm/Shanghai Junshi Biosciences) | JS-501; HOT-1010 | Phase 3 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Details |
| Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) | HD-204 | Phase 3 Clinical | Hanwha Biologics | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Alphamab/R-Pharm) | RPH-001 | Phase 3 Clinical | R-Pharm Jsc, Suzhou Alphamab Co Ltd | Colorectal Neoplasms | Details |
| Bevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical) | TRS-003 | Phase 3 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Details |
| Bevacizumab biosimilar (Genor Biopharma) | GB-222 | Phase 3 Clinical | Genor Biopharma Co Ltd | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma | Details |
| JS-207 | JS-207 | Phase 3 Clinical | Dotbio Pte Ltd, Shanghai Junshi Biosciences Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Bevacizumab biosimilar(Enzene Biosciences) | Phase 3 Clinical | Enzene Biosciences Ltd | Colorectal Neoplasms | Details | |
| 4D-150 | 4D-150 | Phase 3 Clinical | 4d Molecular Therapeutics Inc | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Curateq Biologics) | BP01; BP-01 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Colonic Neoplasms | Details |
| Aflibercept biosimilar (Shilpa Biologicals) | SBDM-03 | Phase 3 Clinical | Shilpa Biologicals Pvt Ltd | Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Centus Biotherapeutics) | FKB-238 | Phase 3 Clinical | Fujifilm Kyowa Kirin Biologics Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Aflibercept Biosimilar(Rophibio) | RBS-001 | Phase 3 Clinical | Rophibio Inc | Macular Degeneration; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar(Laboratorios Sophia) | PRO-169 | Phase 3 Clinical | Laboratorios Sophia Sa De Cv | Diabetic macular oedema | Details |
| Aflibercept biosimiliar (Jingze Biotechnology) | JZB05; JZB-05 | Phase 3 Clinical | Chengdu Zeyan Biotechnology Co Ltd, Shanghai Jingze Biotechnology Co Ltd | Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion | Details |
| Bevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu) | K-11 | Phase 3 Clinical | Beijing Lvzhu Biological Technology Co Ltd, Beijing Science Sun Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Details |
| Pumitamig | PM-8002; BMS-986545; PM8002; BNT-327 | Phase 3 Clinical | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Macular Degeneration; Wet Macular Degeneration | Details |
| Varisacumab | R-84; GNR-011; AT-001-IBCG | Phase 3 Clinical | Peregrine, University of Texas Southwestern Medical Center | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma | Details |
| AZD-8601 | mRNA-AZD-8601; AZD-8601 | Phase 2 Clinical | Astrazeneca Plc, Moderna Inc | Heart Failure | Details |
| ALS-L1023 | ALS-L1023 | Phase 2 Clinical | Angiolab Inc | Macular Degeneration; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Obesity, Abdominal; Otitis Media with Effusion; Rosacea; Sleep Bruxism; Temporomandibular Joint Disorders | Details |
| Bevacizumab biosimilar (Eastern Biotech) | JY-028 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Macular Degeneration; Wet Macular Degeneration | Details |
| CS-2009 | CS-2009 | Phase 2 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| ELGN-EYE | ELGN-EYE | Phase 2 Clinical | Elgan Pharma Ltd | Retinopathy of Prematurity | Details |
| ASKG-712 | ASKG-712; AM-712; VIS-101 | Phase 2 Clinical | Askgene Pharma | Diabetic macular oedema; Geographic Atrophy; Macular Degeneration; Wet Macular Degeneration | Details |
| SCT-501(National Cancer Institute) | SCT-501 | Phase 2 Clinical | National Cancer Institute | Kidney Neoplasms | Details |
| Y-400 | Y-400 | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv | Neoplasms; Wet Macular Degeneration | Details |
| SYB-509 | SYB-509 | Phase 1 Clinical | Yuanda Shuyang Life Sciences (Chengdu) Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Transitional Cell | Details |
| Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| Bevacizumab biosimilar (North China Pharmaceutical) | MG-021 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Macular Degeneration | Details |
| Bevacizumab biosimilar(Guilin Sanjin) | Phase 1 Clinical | Guilin Sanjin Pharmaceutical Co Ltd | Macular Degeneration | Details | |
| Ranibizumab biosimilar (CJSC Generium) | GNR-067 | Phase 1 Clinical | Cjsc Generium | Macular Degeneration | Details |
| Bevacizumab biosimilar (JHL Biotech) | JHL-1149 | Phase 1 Clinical | Eden Biologics Inc | Neoplasms | Details |
| Pasireotide long-acting formulation (Camurus) | CAM-4071 | Phase 1 Clinical | Camurus Ab | Endocrine System Diseases | Details |
| Bevacizumab biosimilar (Tanvex BioPharma) | TX-16 | Phase 1 Clinical | Tanvex BioPharma Inc | Colorectal Neoplasms | Details |
| PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| IBI-333 | IBI-333 | Phase 1 Clinical | Macular Degeneration; Wet Macular Degeneration | Details | |
| IBI-324 | IBI-324; OLN324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema; Macular Degeneration | Details |
| EB-105 | EB-105 | Phase 1 Clinical | Eluminex Biosciences (Suzhou) Ltd | Diabetic macular oedema; Diabetic Retinopathy | Details |
| Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Neoplasms; Solid tumours | Details |
| CTX-10726 | CTX-10726 | Phase 1 Clinical | Compass Therapeutics Inc | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
| Aflibercept biosimilar(Generium) | GNR-098 | Phase 1 Clinical | Generium Pharmaceuticals | Macular Degeneration | Details |
| Bevacizumab biosimilar (Gedeon Richter) | Phase 1 Clinical | Gedeon Richter Plc | Neoplasms | Details | |
| HG-202 | HG-202; HG202 | Phase 1 Clinical | HuiGene Therapeutics Ltd | Macular Degeneration; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
| BD-311 | BD311 | Phase 1 Clinical | Shanghai BDgene Co Ltd | Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
| OB-318 | OB-318 | Phase 1 Clinical | Oneness Biotech Co Ltd | Carcinoma, Hepatocellular; Solid tumours | Details |
| Bevacizumab biosimilar(Guangdong Dongyangguang) | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
| Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) | Phase 1 Clinical | Pepscan Systems | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar(Bioxpress) | BXT-2316 | Clinical | Bioxpress Therapeutics Sa | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Bevacizumab biosimilar (Qilu Pharma) | QL-1101 | Approved | Qilu Pharmaceutical Co Ltd | 安可达 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2019-12-06 | Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms | Details |
| Bevacizumab biosimilar (Innovent Biologics) | IBI-305; IBI305; IBI 305; CHS-305 | Approved | 达攸同, BYVASDA, Bevagen | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2020-06-17 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (Pfizer) | PF-6439535; PF-06439535 | Approved | Pfizer Inc | Zirabev | EU | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Pfizer Europe Ma Eeig | 2019-02-14 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Elea) | Approved | Laboratorio Elea Phoenix Sa | Lumiere | Argentina | Macular Degeneration | Laboratorio Elea Phoenix Sa | 2018-04-26 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Samsung Bioepis) | SP-8; SB-8 | Approved | Samsung Bioepis Co Ltd | Aybintio | EU | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Peritoneal Neoplasms | Samsung Bioepis Nl Bv | 2020-08-19 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Ranibizumab biosimilar (Samsung Bioepis) | SB-11; SB11; AM002 | Approved | Samsung Bioepis Co Ltd | BYOOVIZ, Amelivu | EU | Choroidal Neovascularization; Retinal Vein Occlusion; Diabetic macular oedema; Macular Edema; Diabetic Retinopathy; Wet Macular Degeneration | Samsung Bioepis Nl Bv | 2021-08-18 | Choroidal Neovascularization; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Intas Pharmaceuticals) | INTP-24 | Approved | Intas Biopharmaceuticals | Bevatas | India | Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms | Intas Biopharmaceuticals | 2017-10-04 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Ranibizumab biosimilar (Formycon/Bioeq) | CHS-201; FYB-201 | Approved | Bioeq Gmbh, Formycon AG | CIMERLI, Ranivisio | United States | Choroidal Neovascularization; Retinal Vein Occlusion; Macular Edema; Macular Degeneration; Diabetic Retinopathy; Diabetic macular oedema; Wet Macular Degeneration | Sandoz Inc, Coherus Biosciences Inc | 2022-08-02 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (AryoGen Biopharma) | BE1040V | Approved | Aryogen Biopharma | Stivant | Iran | Uterine Cervical Neoplasms; Metastatic breast cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Glioblastoma | Aryogen Biopharma | 2019-06-01 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Metastatic breast cancer; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Shanghai Institute Of Biological Products) | SIBP-04 | Approved | Shanghai Institute of Biological Products Co Ltd | 生唯宁 | Mainland China | Colorectal Neoplasms; Glioblastoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Ovarian Neoplasms | Shanghai Institute of Biological Products Co Ltd | 2025-01-08 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Ovarian Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Zydus Cadila) | Approved | Zydus Cadila | Bryxta | India | Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Glioblastoma; Metastatic breast cancer; Carcinoma, Renal Cell | Zydus Cadila | 2017-01-01 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Metastatic breast cancer; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (TOT Biopharm) | TOT-102; TAB008; TOT102; TAB-008 | Approved | Tot Biopharm Co Ltd | 朴欣汀, Pusintin | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Tot Biopharm Co Ltd | 2021-12-01 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab | G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL | Approved | Genentech Inc | 安维汀, Avastin | United States | Colorectal Neoplasms | Genentech Inc | 2004-02-26 | Abdominal Neoplasms; Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adrenocortical Carcinoma; Angioid Streaks; Arteriovenous Malformations; Ascites; Astrocytoma; Blister; Brain metastases; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Bursitis; Carcinoid Tumor; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Central Serous Chorioretinopathy; Cerebrovascular Disorders; Cholangiocarcinoma; Choroidal Neovascularization; CNS Embryonal Tumor; Colonic Neoplasms; Colorectal Neoplasms; Corneal Neovascularization; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Retinopathy; Disease Attributes; DNA Virus Infections; Endometrial Neoplasms; Ependymoma; Epistaxis; Es | Details |
| Bevacizumab biosimilar(Dr. Reddy's Laboratories) | DRL-BZ | Approved | Dr.Reddy's Laboratories Ltd | Versavo, Persivia | India | Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | Dr.Reddy's Laboratories Ltd | 2019-08-19 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Aflibercept Biosimilar (Alteogen) | ALT-L9 | Approved | Alteogen Inc, Kissei Pharmaceutical Co Ltd | EU | Diabetic macular oedema; Choroidal Neovascularization; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Biolitec Pharma Ltd | 2025-09-15 | Choroidal Neovascularization; Diabetic macular oedema; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details | |
| Bevacizumab biosimilar (Celltrion) | CTP-16; CT-16; CT-P16 | Approved | Celltrion Inc | Vegzelma | EU | Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Carcinoma, Renal Cell | Celltrion Healthcare Hungary Kft | 2022-08-17 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | YESAFILI | EU | Myopia, Degenerative; Diabetic Retinopathy; Retinal Vein Occlusion; Diabetes Complications; Macular Edema | Viatris Ltd | 2023-09-15 | Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Edema; Myopia, Degenerative; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Ranibizumab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Razumab | India | Macular Degeneration | Intas Biopharmaceuticals | 2015-01-01 | Macular Degeneration | Details | |
| Bevacizumab biosimilar (Outlook) | ONS-5010; ONS-1045 | Approved | Outlook Therapeutics Inc | Lytenava | EU | Wet Macular Degeneration | Outlook Therapeutics Ltd | 2024-05-27 | Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Ranibizumab biosimilar (Xbrane) | Approved | Xbrane Biopharma Ab | Ximluci | EU | Macular Edema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy | Stada Arzneimittel Ag | 2022-11-09 | Diabetes Complications; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Wet Macular Degeneration | Details | |
| Bevacizumab biosimilar (Boan Biopharma) | LY-01008; BA-1101 | Approved | Shandong Boan Biotechnology Co Ltd | 博优诺, Boyounuo | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Shandong Boan Biotechnology Co Ltd | 2021-04-30 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Glioblastoma; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Shanghai Henlius Biotech) | HLX-04 | Approved | 汉贝泰 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Shanghai Henlius Biopharmaceuticals Co Ltd | 2021-11-30 | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details | |
| Bevacizumab biosimilar (Biocad) | BCD-021 | Approved | BIOCAD JSC | Avegra | Russian Federation | Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial | BIOCAD JSC | 2015-11-25 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Macular Degeneration; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Sinocelltech) | SCT-510; SCT510A; SCT-510A | Approved | SinoCelltech Ltd | 安贝珠 | Mainland China | Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | SinoCelltech Ltd | 2023-06-27 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Macular Degeneration; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Wet Macular Degeneration | Details |
| Suvemcitug | SIM-BD-0801; EPI-0030; BD-0801; TK-001; APX-003; 9MW0211; 9MW-0211; MW02; MW-02 | Approved | Apexigen Inc, Epitomics Inc | 恩泽舒 | Mainland China | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Jiangsu Xiansheng biopharmaceutical Co Ltd | 2025-06-30 | Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Wet Macular Degeneration | Details |
| Ranibizumab biosimilar (Qilu Pharmaceutical) | BCD-300; QL-1205 | Approved | Biocnd, Qilu Pharmaceutical Co Ltd | Rimmyrah | EU | Myopia, Degenerative; Macular Edema; Wet Macular Degeneration; Choroidal Neovascularization; Diabetes Complications | Qilu Pharma Spain Sa | 2024-01-05 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Myopia; Myopia, Degenerative; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Ranibizumab biosimilar (Lupin) | LUBT-010 | Approved | Lupin Ltd | Ranluspec | EU | Retinal Vein Occlusion; Diabetes Complications; Choroidal Neovascularization; Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy | Lupin Europe Gmbh | 2026-02-10 | Choroidal Neovascularization; Diabetes Complications; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Allergan/Amgen) | ABP-215 | Approved | Amgen Inc | Mvasi | United States | Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma | Amgen Inc | 2017-09-14 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207; QL1207H | Approved | Qilu Pharmaceutical Co Ltd | 卓初明 | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| Ranibizumab biosimilar (Senju) | GBS-007; OT-701; SJP-0133 | Approved | Senju Pharmaceutical Co Ltd | Japan | Macular Degeneration | Senju Pharmaceutical Co Ltd | 2021-09-27 | Macular Degeneration; Wet Macular Degeneration | Details | |
| Aflibercept biosimilar (Amgen) | ABP-938 | Approved | Amgen Inc | PAVBLU | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema | Amgen Inc | 2024-08-23 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Vascular Diseases; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Zaklady) | SDC411; SDC-411 | Approved | Zaklady Farmaceutyczne Polpharma SA | Vgenfli | EU | Choroidal Neovascularization; Retinal Vein Occlusion; Wet Macular Degeneration; Macular Edema; Diabetic macular oedema; Diabetes Complications | Zaklady Farmaceutyczne Polpharma SA | 2025-08-14 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (mAbixience) | MB02; BEVZ-92; BEVZ92-MB02; AP-01 | Approved | Mabxience Sa | Alymsys | Argentina | Colorectal Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Stada Arzneimittel Ag | 2013-10-25 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Neovasculgen | PI-VEGF165 | Approved | Human Stem Cells Institute | Neovasculgen | Russian Federation | Peripheral Arterial Disease | Human Stem Cells Institute | 2011-12-07 | Cystitis; Cystitis, Interstitial; Diabetes Mellitus; Foot Ulcer; Peripheral Arterial Disease; Peripheral Nerve Injuries | Details |
| Bevacizumab biosimilar (CTTQ Pharma) | TQ-B2302 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 安倍斯 | Mainland China | Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-02-28 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Glioblastoma; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Rectal Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Biocon/Mylan) | MYL-1402O | Approved | Biocon Ltd | Lextemy, KRABEVA, Abevmy | India | Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Ovarian Neoplasms; Brain Neoplasms | Mylan Pharmaceuticals Private Ltd | 2017-11-27 | Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Conbercept | FP-3; KH-902; KH902-R10 | Approved | Chengdu Kanghong Biotechnologies Co Ltd | 朗沐, Langmu, Lumitin | Mainland China | Macular Degeneration | Chengdu Kanghong Biotechnologies Co Ltd | 2013-11-27 | Choroidal Neovascularization; Corneal Neovascularization; Diabetes Mellitus; Diabetic macular oedema; Hemangioma; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Retinoblastoma; Uveitis; Vision Disorders; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar(Apotex ) | Approved | Apotex Inc | BAMBEVI | Canada | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Glioblastoma | Apotex Inc | 2021-09-23 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Glioblastoma; Peritoneal Neoplasms | Details | |
| Aflibercept | BAY-865321; BAT-86-5321 | Approved | Bayer AG, Regeneron Pharmaceuticals Inc | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Carcinoma, Non-Small-Cell Lung; Cataract; Central Serous Chorioretinopathy; Choroid Diseases; Choroidal Neovascularization; Colonic Neoplasms; Colorectal Neoplasms; Corneal Neovascularization; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic macular oedema; Diabetic Retinopathy; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Glaucoma, Neovascular; Lymphoma, Non-Hodgkin; Macular Degeneration; Macular Edema; Multiple Myeloma; Myopia, Degenerative; Neoplasm Metastasis; Neoplasms; Polypoidal choroidal vasculopathy; Prostatic Neoplasms; Rectal Neoplasms; Retinal Degeneration; Retinal Diseases; Retinal Vein Occlusion; Retinitis Pigmentosa; Retinopathy of Prematurity; Vitreous Hemorrhage; Wet Macular Degeneration | Details |
| Aflibercept Biosimilar (Alvotech Swiss) | AVT-29; AVT-06 | Approved | Alvotech Swiss Ag | Mynzepli | EU | Wet Macular Degeneration; Macular Edema; Choroidal Neovascularization; Diabetes Complications; Retinal Vein Occlusion | Stada Arzneimittel Ag, null | 2025-08-18 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Eye Diseases; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Vascular Diseases; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Jiangsu Hengrui Medicine) | BP-102 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妥 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2021-06-22 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Approved | Hexal, Sandoz | ENZEEVU, Afqlir | United States | Wet Macular Degeneration | Sandoz Inc | 2024-08-09 | Diabetes Complications; Macular Degeneration; Macular Edema; Retinal Diseases; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Celltrion) | CT-P42 | Approved | Celltrion Inc | Eydenzelt | South Korea | Wet Macular Degeneration; Diabetic macular oedema | Celltrion Inc | 2024-05-30 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Ziv-aflibercept | AVE-0005; BAY-865321 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid | Details |
| Ranibizumab | RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab; rhuFab-V2; Y-0317; RFB-002; RG-6321 | Approved | Genentech Inc, Novartis Pharma Ag | Lucentis, 诺适得, Susvimo | United States | Macular Degeneration | Genentech Inc | 2006-06-30 | Angioid Streaks; Breast Neoplasms; Cardiovascular Diseases; Cataract; Central Serous Chorioretinopathy; Choroidal Neovascularization; Conjunctival Neoplasms; Corneal Neovascularization; Depression; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic macular oedema; Diabetic Retinopathy; Epistaxis; Eye Diseases; Glaucoma; Glaucoma, Neovascular; Glaucoma, Open-Angle; Hemangioma; Histoplasmosis; Iris Diseases; Ischemia; Macular Degeneration; Macular Edema; Macular telangiectasia; Macular telangiectasia 2; Melanoma; Multifocal Choroiditis; Myopia; Myopia, Degenerative; Neovascularization, Pathologic; Optic Neuropathy, Ischemic; Pathologic Processes; Polypoidal choroidal vasculopathy; Port-Wine Stain; Pseudoxanthoma Elasticum; Pterygium; Retinal Degeneration; Retinal Detachment; Retinal Diseases; Retinal Neovascularization; Retinal Telangiectasis; Retinal Vein Occlusion; Retinoblastoma; Retinopathy of Prematurity; Strongyloidiasis; Telangiectasia, Hereditary Hemorrhagic; Telangiectasis; Uvei | Details |
| Aflibercept biosimilar (Bioeq) | FYB-203 | Approved | Formycon AG | AHZANTIVE, Baiama | United States | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Retinal Vein Occlusion; Macular Degeneration | Formycon AG | 2024-06-28 | Choroidal Neovascularization; Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Approved | Samsung Bioepis Co Ltd | OPUVIZ, Opuviz, AFILIVU | United States | Diabetic macular oedema; Macular Edema; Wet Macular Degeneration; Diabetic Retinopathy | Samsung Bioepis Co Ltd | 2024-05-20 | Diabetes Complications; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Reliance Life Sciences) | R-TPR-023 | Approved | Reliance Life Sciences | BevaciRel | India | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Carcinoma, Renal Cell; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms | Reliance Life Sciences | 2016-06-13 | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Hualan Biological Engineering) | WBP-264 | Approved | Hualan Ankang Biotechnology Co Ltd | Mainland China | Peritoneal Neoplasms; Uterine Cervical Neoplasms; Colorectal Neoplasms; Glioblastoma; Carcinoma, Hepatocellular; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Hualan Genetic Engineering Co Ltd | 2024-11-15 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details | |
| Faricimab | RO-6867461; RG-7716 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo, 罗视佳 | United States | Wet Macular Degeneration; Diabetic macular oedema | Genentech Inc | 2022-01-28 | Choroid Diseases; Choroidal Neovascularization; Diabetes Complications; Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Macular Edema; Myopia; Polypoidal choroidal vasculopathy; Retinal Diseases; Retinal Vein Occlusion; Vision Disorders; Wet Macular Degeneration | Details |
| Ivonescimab | AK-112; SMT-112 | Approved | Zhongshan Akeso Biopharma Co Ltd | 依达方 | Mainland China | Carcinoma, Non-Small-Cell Lung | Akeso-Sino Pharma Co Ltd | 2024-05-24 | Adenocarcinoma, Clear Cell; Adrenocortical Carcinoma; Bile Duct Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Lobular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endocrine System Diseases; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Genital Neoplasms, Female; Glioblastoma; Kidney Neoplasms; Lung Neoplasms; Mesothelioma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Paget Disease, Extramammary; Pancreatic Neoplasms; Paraganglioma; Penile Neoplasms; Perivascular Epithelioid Cell Neoplasms; Pheochromocytoma; Prostatic Neoplasms; Rectal Neoplasms; Rhabdomyosarcoma; Salivary Gland Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymus Neoplasms; Tri | Details |
| Aflibercept Biosimilar (Boan Biopharma/Luye Pharma） | LY-09004; BA-9101; OT-702 | Approved | Shandong Boan Biotechnology Co Ltd | 博优景 | Mainland China | Wet Macular Degeneration; Diabetic macular oedema | Shandong Boan Biotechnology Co Ltd | 2025-11-25 | Diabetic macular oedema; Macular Degeneration; Wet Macular Degeneration | Details |
| Bevacizumab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Cizumab | India | Colorectal Neoplasms | Hetero Drugs Ltd | 2016-06-27 | Colorectal Neoplasms | Details | |
| Bevacizumab biosimilar (Bio-Thera Solutions) | GP-2019; BAT-1706 | Approved | Bio-Thera Solutions Ltd | 普贝希, AVZIVI, POBEVCY | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Bio-Thera Solutions Ltd, BeOne Medicines Ltd | 2021-11-17 | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| Bevacizumab biosimilar (Betta/Mabworks) | MIL-60 | Approved | Beijing Mabworks Biotech Co Ltd, Institute Of Basic Medicine, Chinese Academy Of Medical Sciences | 贝安汀 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2021-11-24 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |